Edition:
India

Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

18.52USD
2:29am IST
Change (% chg)

$0.51 (+2.83%)
Prev Close
$18.01
Open
$18.06
Day's High
$18.60
Day's Low
$17.84
Volume
127,143
Avg. Vol
103,343
52-wk High
$18.86
52-wk Low
$8.43

Latest Key Developments (Source: Significant Developments)

Codexis Reports Third Quarter 2020 Financial Results
Friday, 6 Nov 2020 

Nov 5 (Reuters) - Codexis Inc ::CODEXIS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP LOSS PER SHARE $0.06.Q3 LOSS PER SHARE $0.10.Q3 REVENUE $18.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.  Full Article

Codexis Reports Second Quarter 2020 Financial Results
Friday, 7 Aug 2020 

Aug 6 (Reuters) - Codexis Inc ::CODEXIS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.07.Q2 LOSS PER SHARE $0.11.Q2 REVENUE ROSE 21 PERCENT TO $15 MILLION.Q2 REVENUE ESTIMATE $11.2 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.19 -- REFINITIV IBES DATA.HAVE WITHDRAWN FULL YEAR 2020 FINANCIAL GUIDANCE..  Full Article

Codexis And Molecular Assemblies Partner To Transform The Field Of DNA Synthesis
Tuesday, 23 Jun 2020 

June 23 (Reuters) - Codexis Inc ::CODEXIS AND MOLECULAR ASSEMBLIES PARTNER TO TRANSFORM THE FIELD OF DNA SYNTHESIS.CODEXIS INC - CODEXIS WILL PURCHASE $1 MILLION IN SERIES A PREFERRED STOCK OF MOLECULAR ASSEMBLIES.CODEXIS INC - JOHN NICOLS, CODEXIS' PRESIDENT AND CEO WILL JOIN MOLECULAR ASSEMBLIES' BOARD.CODEXIS - ELIGIBLE TO EARN ADDITIONAL SERIES A PREFERRED STOCK, INCLUDING MILESTONES, TO ACCUMULATE TO OWNERSHIP STAKE IN EXCESS OF 10%.  Full Article

Codexis Inc - Under Takeda Agreement, Takeda Will Make A One Time, Non-Refundable Cash Payment To Company Of $8.5 Mln
Monday, 23 Mar 2020 

March 23 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::CODEXIS INC - UNDER TAKEDA AGREEMENT, TAKEDA WILL MAKE A ONE TIME, NON-REFUNDABLE CASH PAYMENT TO COMPANY OF $8.5 MILLION.CODEXIS INC - ELIGIBLE TO RECEIVE UP TO $22.3 MILLION AS REIMBURSEMENT OF RESEARCH AND DEVELOPMENT FEES AND PRE-CLINICAL MILESTONE PAYMENTS.CODEXIS INC - ELIGIBLE TO RECEIVE SOME DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS IN AGGREGATE OF UP TO $100 MILLION PER TARGET GENE.CODEXIS INC - TAKEDA IS ALSO REQUIRED TO PAY TO COMPANY TIERED ROYALTIES ON NET SALES OF PRODUCTS SOLD BY TAKEDA.  Full Article

Codexis Reports Q4 Non-GAAP Earnings Per Share $0.02
Friday, 28 Feb 2020 

Feb 27 (Reuters) - Codexis Inc ::CODEXIS REPORTS 2019 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.02.Q4 LOSS PER SHARE $0.01.Q4 REVENUE $18.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $21.3 MILLION.SEES FY 2020 REVENUE $78 MILLION TO $82 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.00 -- REFINITIV IBES DATA.OUTLOOK FOR 2020 IS FOR ANOTHER YEAR OF DOUBLE-DIGIT REVENUE GROWTH, UP 14% TO 20% OVER 2019.  Full Article

Codexis And Nestlé Health Science Sign Development Deal
Friday, 10 Jan 2020 

Jan 10 (Reuters) - Codexis Inc ::CODEXIS AND NESTLÉ HEALTH SCIENCE SIGN DEVELOPMENT AGREEMENT TO ADVANCE THERAPEUTIC CANDIDATE TOWARDS CLINICAL STUDIES AND EXTEND STRATEGIC COLLABORATION AGREEMENT.CODEXIS INC - NEW DEAL WITH NESTLÉ WILL ADVANCE DEVELOPMENT OF CDX-7108, LEAD CANDIDATE FOR A POTENTIAL TREATMENT OF A GI DISORDER.CODEXIS INC - ORIGINAL SCA WITH NESTLÉ WILL BE EXTENDED THROUGH END OF 2021 TO SUPPORT DISCOVERY OF THERAPEUTIC CANDIDATES FOR ADDITIONAL DISORDERS.CODEXIS INC - CO, NESTLÉ HEALTH SCIENCE WILL RETAIN JOINT OWNERSHIP OVER RIGHTS TO CDX-7108.  Full Article

Codexis Posts Q3 EPS Of $0.01
Wednesday, 6 Nov 2019 

Nov 5 (Reuters) - Codexis Inc ::CODEXIS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.04.Q3 EARNINGS PER SHARE $0.01.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.Q3 REVENUE ROSE 29 PERCENT TO $22 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA.Q3 REVENUE ESTIMATE $16.7 MILLION -- REFINITIV IBES DATA.AFFIRMING FINANCIAL GUIDANCE FOR 2019.  Full Article

Codexis Reports Q2 2019 Results
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Codexis Inc ::CODEXIS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.08.Q2 LOSS PER SHARE $0.12.Q2 REVENUE $12.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.2 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.AFFIRMING ITS FINANCIAL GUIDANCE FOR 2019.FY2019 REVENUE VIEW $70.5 MILLION -- REFINITIV IBES DATA.  Full Article

Codexis Inc - Announces Signing Of A Codeevolver Platform Agreement With Novartis
Wednesday, 15 May 2019 

May 15 (Reuters) - Codexis Inc ::CODEXIS INC - ANNOUNCES SIGNING OF A CODEEVOLVER PLATFORM AGREEMENT WITH NOVARTIS.CODEXIS - UNDER TERMS, NOVARTIS WILL PAY CO UPFRONT PAYMENT, MILESTONE PAYMENTS UPON SATISFACTORY COMPLETION OF TECHNOLOGY TRANSFER.CODEXIS - WILL BE ELIGIBLE TO GET PAYMENTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS MADE WITH ENZYMES DEVELOPED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY.CODEXIS INC - RECEIVES CERTAIN RIGHTS FOR FUTURE PURCHASES OF ENZYMES DEVELOPED & SOURCED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY.  Full Article

Codexis Entered Into Platform Technology Transfer And License Agreement With Novartis
Tuesday, 7 May 2019 

May 6 (Reuters) - Codexis Inc ::CODEXIS INC - ON MAY 2, 2019 ENTERED INTO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT WITH NOVARTIS PHARMA AG - SEC FILING.CODEXIS -UNDER AGREEMENT,GRANTED TO NOVARTIS WORLDWIDE LICENSE TO USE CO'S CODEEVOLVER PLATFORM TECHNOLOGY TO RESEARCH, DEVELOP,MANUFACTURE NOVEL ENZYMES.CODEXIS INC -UNDER AGREEMENT, NOVARTIS WILL PAY CODEXIS UP TO $14 MILLION OVER APPROXIMATELY NEXT 22 MONTHS.CODEXIS - IF NOVARTIS EXERCISES TERMINATION RIGHT BEFORE MAKING FIRST TECHNOLOGY TRANSFER MILESTONE PAYMENT, NOVARTIS TO MAKE 1-TIME TERMINATION PAYMENT OF $9 MILLION.CODEXIS - IF NOVARTIS EXERCISES TERMINATION RIGHT BEFORE MAKING SECOND TECHNOLOGY TRANSFER MILESTONE PAYMENT, NOVARTIS TO MAKE 1-TIME TERMINATION PAYMENT OF $5 MILLION.  Full Article

BRIEF-Codexis And Molecular Assemblies Partner To Transform The Field Of DNA Synthesis

* CODEXIS AND MOLECULAR ASSEMBLIES PARTNER TO TRANSFORM THE FIELD OF DNA SYNTHESIS